PJP Invesco Pharmaceuticals ETF
Quote as of Aug 26, 2026 19:50 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 130.98 | Day Range | 130.00 – 130.76 |
| 52-Week Range | 90.01 – 131.68 | Volume | 10.79K |
| Avg Volume | 35.66K | AUM | $544.8M (Aug 27, 2026) |
| Expense Ratio | 0.57% | Yield (TTM) | 0.81% |
| NAV | 130.97 | Premium/Discount | -0.70% indicative |
| Inception | Jun 23, 2005 | Holdings | 29 |
| Issuer | Invesco | Exchange | AMEX |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 46137V662 | ISIN | US46137V6627 |
| Management | Not stated in source data | ||
About this ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +8.82% | +20.79% | +19.60% | +25.29% | +45.15% | +18.95% | +10.09% | +7.28% | +10.70% |
| Total return | +8.81% | +21.09% | +20.25% | +25.98% | +46.66% | +20.23% | +11.24% | +8.31% | +12.08% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.57% | Annual cost of a $10,000 investment | $57.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 25, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 33 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | ABT | 5.85% | 270.53K | $31.6M |
| 2 | Amgen Inc | AMGN | 5.74% | 69.80K | $31.0M |
| 3 | Merck & Co Inc | MRK | 5.47% | 195.82K | $29.5M |
| 4 | AbbVie Inc | ABBV | 5.39% | 110.04K | $29.1M |
| 5 | Johnson & Johnson | JNJ | 5.15% | 101.84K | $27.8M |
| 6 | Eli Lilly & Co | LLY | 5.09% | 22.02K | $27.5M |
| 7 | Corcept Therapeutics Inc | CORT | 4.99% | 218.53K | $26.9M |
| 8 | Gilead Sciences Inc | GILD | 4.77% | 175.33K | $25.7M |
| 9 | Pfizer Inc | PFE | 4.70% | 907.06K | $25.4M |
| 10 | Travere Therapeutics Inc | TVTX | 3.60% | 297.83K | $19.4M |
| 11 | Amneal Pharmaceuticals Inc | AMRX | 3.40% | 1.03M | $18.3M |
| 12 | Perrigo Co PLC | PRGO | 3.23% | 1.22M | $17.4M |
| 13 | Regeneron Pharmaceuticals Inc | REGN | 3.19% | 20.78K | $17.2M |
| 14 | Ocular Therapeutix Inc | OCUL | 3.18% | 1.59M | $17.1M |
| 15 | Harmony Biosciences Holdings Inc | HRMY | 3.13% | 438.33K | $16.9M |
| 16 | Ligand Pharmaceuticals Inc | LGND | 2.91% | 56.06K | $15.7M |
| 17 | Tarsus Pharmaceuticals Inc | TARS | 2.91% | 215.65K | $15.7M |
| 18 | Liquidia Corp | LQDA | 2.86% | 219.45K | $15.4M |
| 19 | Bristol-Myers Squibb Co | BMY | 2.83% | 227.29K | $15.3M |
| 20 | Biogen Inc | BIIB | 2.76% | 68.28K | $14.9M |
| 21 | Prestige Consumer Healthcare Inc | PBH | 2.65% | 274.66K | $14.3M |
| 22 | Jazz Pharmaceuticals PLC | JAZZ | 2.62% | 55.59K | $14.1M |
| 23 | Viatris Inc | VTRS | 2.49% | 811.15K | $13.4M |
| 24 | Supernus Pharmaceuticals Inc | SUPN | 2.31% | 276.06K | $12.5M |
| 25 | Innoviva Inc | INVA | 2.27% | 581.49K | $12.2M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.81% | Paid (last 12 months) | $1.0650 |
| Frequency | Quarterly | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Jun 22, 2026 | Last payment | $0.2733 (Jun 26, 2026) |
| Growth 1Y | +10.55% | Growth 3Y / 5Y (ann.) | +14.20% / +14.17% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 22, 2026 | Jun 22, 2026 | Jun 26, 2026 | $0.2733 |
| Mar 23, 2026 | Mar 23, 2026 | Mar 27, 2026 | $0.3090 |
| Dec 22, 2025 | Dec 22, 2025 | Dec 26, 2025 | $0.2463 |
| Sep 22, 2025 | Sep 22, 2025 | Sep 26, 2025 | $0.2363 |
| Jun 23, 2025 | Jun 23, 2025 | Jun 27, 2025 | $0.2668 |
| Mar 24, 2025 | Mar 24, 2025 | Mar 28, 2025 | $0.2729 |
| Dec 23, 2024 | Dec 23, 2024 | Dec 27, 2024 | $0.2232 |
| Sep 23, 2024 | Sep 23, 2024 | Sep 27, 2024 | $0.2004 |
| Jun 24, 2024 | Jun 24, 2024 | Jun 28, 2024 | $0.2105 |
| Mar 18, 2024 | Mar 19, 2024 | Mar 22, 2024 | $0.1695 |
| Dec 18, 2023 | Dec 19, 2023 | Dec 22, 2023 | $0.1913 |
| Sep 18, 2023 | Sep 19, 2023 | Sep 22, 2023 | $0.2013 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 16.88% / 16.28% | Sharpe 1Y / 3Y | 2.68 / 1.12 |
| Max drawdown 1Y / 3Y | -9.44% / -16.27% | Sortino 1Y | 4.48 |
| Beta vs S&P 500 (3Y) | 0.524 | Correlation vs S&P 500 (1Y) | 0.318 |
| Downside deviation 1Y | 10.10% | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 10.79K | Average volume | 35.66K |
| AUM | $544.8M | Premium/Discount | -0.70% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $3.7M | +0.69% | $535.6M → $539.2M |
| 1 Week | $24.8M | +4.80% | $517.0M → $539.2M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for PJP
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.